ziprasidone + Standard therapy
ApprovedWithdrawn 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Psychosis
Conditions
Psychosis, Agitation, Delirium
Trial Timeline
Sep 1, 2008 → Jul 1, 2011
NCT ID
NCT00786318About ziprasidone + Standard therapy
ziprasidone + Standard therapy is a approved stage product being developed by Pfizer for Psychosis. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT00786318. Target conditions include Psychosis, Agitation, Delirium.
What happened to similar drugs?
2 of 16 similar drugs in Psychosis were approved
Approved (2) Terminated (0) Active (14)
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00786318 | Approved | Withdrawn |
Competing Products
20 competing products in Psychosis